[摘 要] 目的：探讨叉头框K1（FOXK1）在喉鳞状细胞癌（LSCC）中的表达、临床意义及对细胞增殖、迁移、侵袭的影响，并阐明其分子机制。方法：RT-qPCR、免疫组化检测LSCC组织及LSCC细胞TU177中FOXK1表达，分析其与临床病理参数及预后的相关性；通过瞬时转染构建FOXK1过表达与敲低细胞模型，通过MTS法、克隆形成实验、划痕愈合实验和Transwell实验检测细胞恶性生物学行为的变化；采用RT-qPCR检测上皮-间充质转化（EMT）相关因子mRNA的表达；采用WB法检测PI3K/AKT信号通路相关蛋白的表达；结合生物信息学预测与功能回复实验，验证FOXK1对AKT2的调控作用。结果：FOXK1在LSCC组织及细胞中高表达（P < 0.01），且主要定位于细胞核；FOXK1高表达与较晚TNM分期相关（P < 0.05），且FOXK1高表达患者5年生存率较低（P < 0.05）；过表达FOXK1显著增强TU177细胞增殖、迁移与侵袭能力并诱导EMT（P < 0.01或P < 0.05），敲低FOXK1则产生相反的效应；FOXK1可上调AKT2表达并激活PI3K/AKT信号通路；敲低AKT2可部分逆转FOXK1过表达对细胞增殖、迁移、侵袭及EMT进程的促进作用（P < 0.01或P < 0.05）。结论：FOXK1在LSCC中高表达，与肿瘤进展及不良预后密切相关。FOXK1可能通过上调AKT2激活PI3K/AKT信号通路，诱导EMT，从而促进LSCC细胞的恶性生物学行为。

[Abstract] Objective: To construct CD33-CAR modified NK92 cells based on CD33-scFv sequence, and to explore its killing effect on CD33+ AML (acute myeloid leukemia) cells. Methods: DNA fragment encoding CD33-CAR was synthesized by gene synthesis and molecular cloning technology and then cloned into lentiviral vector. Lentivirus were packaged and used to transfect NK92 cells. The transfection efficiency was detected by flow cytometry, and puromycin was used to screen NK92 cells stably expressing CD33-CAR (CD33-CAR-NK92). Killing effect of CD33-CAR-NK92 cells on AML cells in vitro was examined with calcein-AM release assays. IFN-γ secretions of NK92 cells and CD33-CAR-NK92 cells were measured by ELISA. Results: The pCDH-CD33-CAR lentiviral vector was successfully constructed. After lentiviral transfection, about 18.7% of NK92 cells express CD33-CAR (referred as CD33-CARNK92 cells). The percentage of CD33-CAR+ NK92 cells was about 86.3% after puromycin selection. In contrast to unmodified NK92 cells, significantly higher cytotoxic effect against CD33+ MOLM-13 cells was found in CD33-CAR-NK92 cells (P<0.01); however, there was no significant difference in cytotoxicity against CD33- JURKAT cells between NK92 cells and CD33-CAR-NK92 cells (P> 0.05). After co-culture at an effect-target ratio of 2∶1 for 6 hours, the level of IFN-γ secreted by the CD33-CAR modified NK92 cells was significantly higher than that of the unmodified ([190.97±11.52] vs [88.41±2.75]pg/ml, P<0.01). Conclusion: The CD33-CARNK92 cells could specifically recognize CD33 antigen and kill CD33+ AML cells in comparison with the unmodified NK92 cells, which provides experimental basis for clinical transformation of CD33-CAR-NK92 cells in treatingAML.